TITLE

Warfarin Sensitivity Genotyping: A Review of the Literature and Summary of Patient Experience

AUTHOR(S)
MOYER, THOMAS P.; O'KANE, DENNIS J.; BAUDHUIN, LINNEA M.; WILEY, CARMEN L.; FORTINI, ALEXANDRE; FISHER, PAMELA K.; DUPRAS, DENISE M.; CHAUDURY, RAJEEV; THAPA, PRABIN; ZINSMEISTER, ALAN R.; HEIT, JOHN A.
PUB. DATE
December 2009
SOURCE
Mayo Clinic Proceedings;Dec2009, Vol. 84 Issue 12, p1079
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The antithrombotic benefits of warfarin are countered by a narrow therapeutic index that contributes to excessive bleeding or cerebrovascular clotting and stroke In some patients. This article reviews the current literature describing warfarin sensitivity genotyping and compares the results of that review to the findings of our study in 189 patients at Mayo Clinic conducted between June 2001 and April 2003. For the review of the iiterature, we identified relevant peer-reviewed articles by searching the Web of Knowledge using key word warfarin-related adverse event. For the 189 Mayo Clinic patients initiating warfarin therapy to achieve a target International normalized ratio (INR) in the range of 2.0 to 3.5, we analyzed the CYP2C9 (cytochrome P450 2C9) and VKORC1 (vitamin K epoxide reductase complex, subunit 1) genetic loci to study the relationship among the Initial warfarin dose, steady-state dose, time to achieve steady-state dose, variations in 1NR, and allelic variance. Results were compared with those previously reported In the literature for 637 patients. The relationships between allelic variants and warfarin sensitIvity found in our study of Mayo Clinic patients are fundamentally the same as In those reported by others. The Mayo Clinic population is predominantly white and shows considerable allelic variability in CYP2C9 and VKORC1. Certain of these alleles are associated with Increased sensitivity to warfarin Polymorphisms in CYP2C9 and VKORC1 have a considerable effect on warfarin dose In white people. A correlation between steady-state warfarin dose and allelic variants of CYP2C9 and VKORC1 has been demonstrated by many previous reports and is reconfirmed in this report. The allelic variants found to most affect warfarin sensitivity are CYP2C9*1*1- VKORC1BB (less warfarin sensitivity than typical); CYP2C9*1*1. VKORC1AA (considerable variance in INR throughout initiation); CYP2C9*1*2-VKORC1AB (more sensitivity to warfarin than typical); CYP2C9*1*3-VKORC1AB (much more sensitivity to warfarin than typical); CYP2C9*1*2-VKORC1AB (much more sensitivity to warfarin than typical); CYP2C9*1*3-VKORC1AA (much more sensitivity to warfarin than typical); and CYP2C9*2*2-VKORC2AB (much more sensitivity to warfarin than typical). Although we were unable to show an association between allelic variants and initial warfarin dose or dose escalation, an association was seen between allelic variant and steady-state warfarin dose. White people show considerable variance in CYP2C9 allele types, whereas people of Asian or African descent Infrequently carry CYP2C9 allelic variants. The VKORC1AA allele associated with high warfarin sensitivity predominates in those of Asian descent, whereas white people and those of African descent show diversity, carrying either the VKORC1BB, an allele associated with low warfarin sensitivity, or VKORC1AB or VKORC1AA, alleles associated with moderate and high warfarin sensitivity, respectively.
ACCESSION #
45895950

 

Related Articles

  • Neue Antikoagulanzien, neue Notfälle? Djalali, Sima // Praxis (16618157);7/24/2013, Vol. 102 Issue 15, p945 

    No abstract available.

  • Oral Vitamin K for Excessive Anticoagulation. Artz, Andrew S. // Clinical Oncology Alert;Apr2009, Vol. 25 Issue 4, p25 

    Warfarin is a frequently prescribed oral anticoagulant. The highly variable, dose-response characteristics mandate monitoring, and this is usually accomplished by targeting an international normalized ratio (INR) value between 2.0 to 3.0. Non-therapeutic values are common, and values above 4.5...

  • The progress of prothrombin time measurement. Horsti, Juha // Hematology Reviews;2009, Vol. 1 Issue 2, p99 

    Warfarin is the most widely used medicine for oral anticoagulant therapy (OAT). It inhibits the synthesis of coagulation factors II, VII, IX, and X in the liver and results in the production of inactive or partially active versions of these factors. Inactive coagulation factors interfere with...

  • Independent Nurse: Clinical Top 50 - Oral anticoagulation. Provan, Drew // GP: General Practitioner;12/2/2005, p121 

    This article reports that therapeutic anticoagulation is increasing by 20 percent each year. By 1996, more than 300,000 British patients required oral anticoagulation. It is informed that warfarin is the preferred oral anticoagulant; phenindione is used in cases of warfarin allergy. Oral...

  • Practical management of coagulopathy associated with warfarin. Garcia, David; Crowther, Mark A.; Ageno, Walter // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;4/24/2010, Vol. 340 Issue 7752, p918 

    The article discusses a practical management strategy for a patient with coagulopathy associated with warfarin. It cites several clinical questions that emerge when patients who take vitamin K antagonists are suffering from bleeding or having an international normalised ratio above the...

  • Anticoagulant-related bleeding: into the unknown? Key, Nigel S. // Hem/Onc Today;6/25/2008, Vol. 9 Issue 11, p4 

    The author reflects on the issue of major bleeding associated with anticoagulation therapy and the search for the perfect coagulant. He enumerates the characteristics of the ideal anticoagulant proposed by several researchers. He examines the advantages of the anticoagulant warfarin over other...

  • Rectus sheath hematoma in elderly, medical or surgical treatment? Marti, Juan // Internet Journal of Internal Medicine;2009, Vol. 8 Issue 1, p18 

    Anticoagulation induced bleeding complications to occur more frequently in the elderly. Two patients with Rectus sheath hematoma as a result of bleeding complication of warfarine therapy are reported.

  • Fondaparinux or Enoxaparin for Deep Venous Thrombosis?  // Annals of Internal Medicine;6/1/2004, Vol. 140 Issue 11, p44 

    This article presents information on the use of fondaparinux or enoxaparin for deep venous thrombosis. Deep venous thrombosis (DVT) is caused by a blood clot inside the deep veins of the legs. Pieces of the clot can break off, travel to the lungs, and cause serious and even fatal complications....

  • VKORC1 Gene Analysis of Some Iranian Sensitive Patients to Warfarin. Kianmehr, Z.; Ghadam, P.; Sadrai, S.; Kazemi, B.; Sharifian, R. A. // Pakistan Journal of Biological Sciences;2010, Vol. 13 Issue 18, p906 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics